8-K: Tonix Pharmaceuticals Advances Tonmya for Fibromyalgia with FDA Meeting and NDA Filing Planned

Tonix Pharmaceuticals has completed a key meeting with the FDA regarding its drug candidate Tonmya for fibromyalgia and is preparing for a New Drug Application submission.

Summary

• Tonix Pharmaceuticals is focused on developing Tonmya (TNX-102 SL) for fibromyalgia management.
• The company has completed two Phase 3 trials with statistically significant results on the primary endpoint for Tonmya.
• A New Drug Application (NDA) filing with the FDA is expected in the second half of 2024, with a decision on approval anticipated in the second half of 2025.
• Tonmya is a sublingual formulation of cyclobenzaprine designed to optimize delivery and absorption, targeting non-restorative sleep.
• The company has also completed a Type B CMC and clinical pre-NDA meeting with the FDA and is awaiting formal minutes.
• Tonix is also exploring additional indications for Tonmya, including fibromyalgia-type Long COVID and acute stress disorder.
• The company has acquired two marketed migraine drugs, Zembrace and Tosymra, to prepare for the launch of Tonmya.
• Tonix is also developing other drug candidates for cocaine intoxication, organ transplant rejection, and Prader-Willi syndrome.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Tonix, highlighting the successful Phase 3 trial results for Tonmya and the upcoming NDA filing. The company's strategic partnerships and diverse pipeline also contribute to a strong positive sentiment.

Positives

• Tonmya has shown statistically significant efficacy in reducing pain, fatigue, and sleep disturbances in fibromyalgia patients.
• The sublingual formulation of Tonmya allows for rapid absorption and avoids first-pass metabolism.
• Tonmya has a unique mechanism of action, targeting multiple receptors involved in sleep and pain regulation.
• The company has a strong patent portfolio for Tonmya, providing exclusivity until 2034/2035.
• Tonix has secured partnerships with government and academic institutions, providing funding and support for clinical trials.
• The company has a commercial infrastructure in place with two marketed migraine drugs, which can be leveraged for the launch of Tonmya.
• Tonmya has shown a potential tolerability advantage over existing fibromyalgia drugs, with fewer side effects.

Negatives

• The Phase 2 PREVAIL study for TNX-102 SL in fibromyalgia-type Long COVID did not meet its primary endpoint of multi-site pain reduction.
• The RALLY Phase 3 study for Tonmya missed its primary endpoint, although the RESILIENT study was successful.
• Oral administration site adverse events were higher in the TNX-102 SL group compared to placebo in the RESILIENT study.
• There is a risk of study discontinuations due to adverse events, although most are mild or moderate.
• The company is dependent on third parties for research and development efforts.

Risks

• There are risks related to obtaining FDA clearances or approvals for Tonmya.
• The company faces risks related to the successful marketing of its products.
• There are risks related to the timing and progress of clinical development of product candidates.
• The company has a need for additional financing.
• There are uncertainties of patent protection and litigation.
• There are uncertainties of government or third-party payor reimbursement.
• The company faces substantial competition in the pharmaceutical market.

Future Outlook

Tonix plans to file an NDA for Tonmya in the second half of 2024 and anticipates an FDA decision on approval in the second half of 2025. The company is also advancing clinical trials for other indications of Tonmya and other drug candidates.

Management Comments

• Tonix is committed to developing and marketing therapeutics to treat pain, neurologic, psychiatric and addiction conditions.
• The company is focused on filing a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for Tonmya (TNX 102 SL) for the management of Fibromyalgia.

Industry Context

The document highlights the significant unmet need for effective fibromyalgia treatments, as current FDA-approved drugs have limitations in efficacy and tolerability. The company is positioning Tonmya as a novel treatment option with a unique mechanism of action and improved tolerability. The document also notes the trend of big pharma acquiring companies with de-risked commercial launches, suggesting a potential future strategy for Tonix.

Comparison to Industry Standards

• The document compares Tonmya to existing FDA-approved fibromyalgia drugs like Pregabalin (Lyrica), Duloxetine (Cymbalta), and Milnacipran (Savella), highlighting Tonmya's potential advantages in terms of tolerability and broad symptom improvement.
• The document notes that current fibromyalgia drugs were repurposed from other indications, while Tonmya is specifically designed for fibromyalgia.
• The document references the success of other CNS drug launches, such as Auvelity (Axsome), Nurtec (Biohaven), Caplyta (IntraCellular), Ingrezza (Neurocrine), and Nuplazid (Acadia), suggesting a potential path for Tonmya.
• The document mentions Sanofi's frexalimab, an Fc-modified anti-CD40L mAb, as a potential competitor in the autoimmune space, highlighting the importance of TNX-1500's similar modification to reduce thrombosis risk.

Stakeholder Impact

• Shareholders may benefit from the potential approval and commercialization of Tonmya.
• Patients with fibromyalgia may have a new treatment option with improved efficacy and tolerability.
• Employees may benefit from the company's growth and success.
• The company's partnerships with government and academic institutions may lead to further advancements in drug development.

Next Steps

• The company will await formal minutes from the Type B CMC and clinical pre-NDA meetings with the FDA.
• Tonix plans to submit an NDA to the FDA for Tonmya in the second half of 2024.
• The company expects an FDA decision on NDA approval for Tonmya in the second half of 2025.
• Tonix will meet with the FDA regarding the primary endpoint for the Long COVID program.
• The company expects to start a Phase 2 study for TNX-102 SL in acute stress disorder in Q2 2024.
• The company expects to start a Phase 2 study for TNX-1300 for the treatment of cocaine intoxication in Q2 2024.

Key Dates

Keywords

Tonmya, TNX-102 SL, Fibromyalgia, NDA, FDA, Cyclobenzaprine, Sublingual, Chronic Pain, Long COVID, Acute Stress Disorder, RESILIENT, Clinical Trial, Pharmaceuticals, Drug Development